Q-omics provides the consensus-scored ZNF233 profile across patient tissues and cancer cell-line models. ZNF233 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, ZNF233 is differentially expressed in 11, with the highest sampling consensus in KIRP. Additionally, ZNF233 RNA expression shows 20,929 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LIHC, KIRP, and THYM as cancer lineages where ZNF233 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF233 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF233 survival associations across molecular data types. ZNF233 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF233 RNA expression–survival associations across cancer types. High ZNF233 expression shows unfavorable associations in LIHC, LUSC and DLBC, but favorable associations in HNSC, PAAD and THCA. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for ZNF233 RNA expression.
This table summarizes ZNF233 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF233. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF233 shows lower tumor expression in KIRP, KIRC and COAD and higher tumor expression in BRCA, LIHC and LUAD. The KIRP box plot shows higher ZNF233 RNA expression in normal versus tumor tissue (log2 FC = −0.804, t-test p < 0.001).
This table shows molecular features associated with ZNF233 in patient tissues and cancer cell lines. In patient samples, ZNF233 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF233 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
